Blinatumomab in Relapsed/Refractory Burkitt Lymphoma by Jeanne Bohler, Ulrike Bacher, Yara Banz, Raphael Stadelmann, Michael Medinger, Thilo Zander, Thomas Pabst

Subjects: “…Burkitt lymphoma (BL)…”
Get full text

CAR T-Cell Persistence Correlates with Improved Outcome in Patients with B-Cell Lymphoma by Valerie Wittibschlager, Ulrike Bacher, Katja Seipel, Naomi Porret, Gertrud Wiedemann, Claudia Haslebacher, Michèle Hoffmann, Michael Daskalakis, Dilara Akhoundova, Thomas Pabst

Subjects: Get full text

Transformed Lymphoma Is Associated with a Favorable Response to CAR-T-Cell Treatment in DLBCL Patients by Anna Nydegger, Urban Novak, Marie-Noëlle Kronig, Myriam Legros, Sacha Zeerleder, Yara Banz, Ulrike Bacher, Thomas Pabst

Subjects: “…diffuse large B-cell lymphoma (DLBCL)…”
Get full text

Experiences with Glofitamab Administration following CAR T Therapy in Patients with Relapsed Mantle Cell Lymphoma by Alexander D. Heini, Ulrike Bacher, Naomi Porret, Gertrud Wiedemann, Myriam Legros, Denise Stalder Zeerleder, Katja Seipel, Urban Novak, Michael Daskalakis, Thomas Pabst

Subjects: “…mantle cell lymphoma (MCL)…”
Get full text

Comprehensive Laboratory Diagnostic Workup for Patients with Suspected Intraocular Lymphoma including Flow Cytometry, Molecular Genetics and Cytopathology by Evgenii Shumilov, Paolo Mazzeo, Martin S. Zinkernagel, Myriam Legros, Naomi Porret, Lorenz Romagna, Detlef Haase, Georg Lenz, Urban Novak, Yara Banz, Thomas Pabst, Ulrike Bacher

Subjects: “…intraocular lymphoma…”
Get full text

Evaluation of Bortezomib-BeEAM (2BeEAM) as Chemotherapy Regimen Prior to ASCT in Patients with Mantle Cell Lymphoma by Fabrizio Huwyler, Rebekka Kunz, Ulrike Bacher, Michèle Hoffmann, Urban Novak, Michael Daskalakis, Yara Banz, Thomas Pabst

Subjects: Get full text

OUTCOME OF PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA RELAPSING AFTER AUTOLOGOUS TRANSPLANT BEFORE AVAILABILITY OF CAR-T CELL TREATMENT by Ulrike Bacher, Stefanie von Matt, Yara Banz, Behrouz Mansouri Taleghani, Urban Novak, Thomas Pabst

Subjects: “…diffuse large B-cell lymphoma (DLBCL)…”
Get full text

Combining BeEAM with Brentuximab Vedotin for High-Dose Therapy in CD30 Positive Lymphomas before Autologous Transplantation—A Phase I Study by Christian Rausch, Ulrike Bacher, Manuela Rabaglio, Corinne Vorburger, Anke Klingenberg, Yara Banz, Michael Daskalakis, Thomas Pabst

Subjects: Get full text

Correlation of Peripheral Chimeric Antigen Receptor T-cell (CAR-T Cell) mRNA Expression Levels with Toxicities and Outcomes in Patients with Diffuse Large B-cell Lymphoma by Christian Messerli, Gertrud Wiedemann, Naomi Porret, Michael Nagler, Katja Seipel, Barbara Jeker, Urban Novak, Sacha Zeerleder, Ulrike Bacher, Thomas Pabst

Subjects: “…non-hodgkin lymphoma…”
Get full text

Low-Frequency <i>PPM1D</i> Gene Mutations Affect Treatment Response to CD19-Targeted CAR T-Cell Therapy in Large B-Cell Lymphoma by Katja Seipel, Michèle Frey, Henning Nilius, Dilara Akhoundova, Yara Banz, Ulrike Bacher, Thomas Pabst

Subjects: “…Diffuse Large B-cell Lymphoma (DLBCL)…”
Get full text

Glofitamab Treatment in Relapsed or Refractory DLBCL after CAR T-Cell Therapy by Vera Rentsch, Katja Seipel, Yara Banz, Gertrud Wiedemann, Naomi Porret, Ulrike Bacher, Thomas Pabst

Subjects: “…diffuse large B-cell lymphoma (DLBCL)…”
Get full text

Chimeric antigen receptor‐T cell therapy shows similar efficacy and toxicity in patients with diffuse large B‐cell lymphoma aged 70 and older compared to younger patients: A multicenter cohort study by Philipp Berning, Evgenii Shumilov, Markus Maulhardt, Hristo Boyadzhiev, Andrea Kerkhoff, Simon Call, Christian Reicherts, Anna O. Saidy, Enver Aydilek, Michèle Hoffmann, Urban Novak, Michael Daskalakis, Norbert Schmitz, Matthias Stelljes, Gerald Wulf, Ulrike Bacher, Georg Lenz, Thomas Pabst

“…Abstract CD19‐directed chimeric antigen receptor (CAR)‐T cell therapy has become a standard treatment for relapsed/refractory diffuse large B‐cell lymphoma (r/r DLBCL). While the benefits of CAR‐T cell treatment are clear in the general patient population, there remains a relative scarcity of real‐world evidence regarding its efficacy and toxicity in patients (pts) aged ≥70 years with DLBCL. …”
Get full text

Humoral Responses to Repetitive Doses of COVID-19 mRNA Vaccines in Patients with CAR-T-Cell Therapy by Simona Gössi, Ulrike Bacher, Claudia Haslebacher, Michael Nagler, Franziska Suter, Cornelia Staehelin, Urban Novak, Thomas Pabst

Subjects: “…diffuse large B-cell lymphoma (DLBCL)…”
Get full text

Rationale for Combining the BCL2 Inhibitor Venetoclax with the PI3K Inhibitor Bimiralisib in the Treatment of IDH2- and FLT3-Mutated Acute Myeloid Leukemia by Katja Seipel, Yvo Brügger, Harpreet Mandhair, Ulrike Bacher, Thomas Pabst

Subjects: Get full text

HSP90 Inhibitor PU-H71 in Combination with BH3-Mimetics in the Treatment of Acute Myeloid Leukemia by Katja Seipel, Scarlett Kohler, Ulrike Bacher, Thomas Pabst

Subjects: Get full text

The Evolving Treatment Landscape of AML by Sabine Blum, Ulrike Bacher, Thomas Pabst

“…Over the last years, B-cell lymphoma-2 (BCL-2), a key regulator of the intrinsic apoptotic pathway, has also emerged as a relevant target for therapy for many diseases including AML, and promising results were reported with the use of BCL-2 inhibitors. …”
Get full text

CAR-T Cell Therapy Shows Similar Efficacy and Toxicity in Patients With DLBCL Regardless of CNS Involvement by Evgenii Shumilov, Hristo Boyadzhiev, Paolo Mazzeo, Dilara Akhoundova, Michael Daskalakis, Urban Novak, Georg Lenz, Ulrike Bacher, Thomas Pabst

“…Efficacy and toxicity of chimeric antigen receptor T (CAR-T) cell therapy in relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL) with central nervous system (CNS) involvement remain understudied. …”
Get full text

Clinical Impact of Single Nucleotide Polymorphism in CD-19 on Treatment Outcome in FMC63-CAR-T Cell Therapy by Katja Seipel, Mariesol Abbühl, Ulrike Bacher, Henning Nilius, Michael Daskalakis, Thomas Pabst

“…Chimeric antigen receptor (CAR)-T cell therapy is effective in patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL) with response rates of 63–84% and complete response observed in 43–54%. …”
Get full text

BeEAM High-Dose Chemotherapy with Polatuzumab (Pola-BeEAM) before ASCT in Patients with DLBCL—A Pilot Study by Tanja Stoffel, Ulrike Bacher, Yara Banz, Michael Daskalakis, Urban Novak, Thomas Pabst

“…(1) Introduction: BEAM is a high-dose chemotherapy (HDCT) frequently administered before autologous stem cell transplantation (ASCT) in diffuse large B-cell lymphoma (DLBCL). Bendamustine replacing BCNU (BeEAM) is similarly effective at lower toxicities. …”
Get full text

Rationale for a Combination Therapy Consisting of MCL1- and MEK-Inhibitors in Acute Myeloid Leukemia by Katja Seipel, Karin Schmitter, Ulrike Bacher, Thomas Pabst

“…Here, we assessed the MCL1-antagonist S63845, the MDM2-inhibitor HDM201, and the MEK1/2-inhibitor trametinib as single agents and in combination in a variety of AML cell lines and mononuclear cells isolated from patients with hematological malignancies centered on myeloid leukemia, some lymphatic leukemia, as well as some lymphomas, for their ability to induce apoptosis and cell death. …”
Get full text